<DOC>
	<DOCNO>NCT01375010</DOCNO>
	<brief_summary>The purpose study determine effect vitamin D measure bone health immune function HIV infect postmenopausal woman . The investigator prior research population reveal low vitamin D level common . Prior research population also reveal Vitamin D necessary body absorb calcium important health bone . When vitamin D level low , increased risk bone loss , muscle weakness , fall fracture . Low level vitamin D also associate impaired immune function . This study help u learn whether two different dos vitamin D improve bone health immune function .</brief_summary>
	<brief_title>Vitamin D HIV Study</brief_title>
	<detailed_description>The purpose study determine effect vitamin D repletion rate bone loss index immune function HIV+ postmenopausal woman . Lower baseline serum Vitamin D level , assess measure serum 25-hydroxyvitamin D ( 25-OHD ) associate trend toward bone loss . In addition , investigator find despite provide supplement contain approximately 600 IU vitamin D , serum 25-OHD increase first year . Provision adequate calcium vitamin D cornerstone effective prevention therapy osteoporosis . HIV-infected patient may increase risk vitamin D deficiency take several medication may interfere vitamin D action . Therefore , investigator recruit 100 HIV infect postmenopausal woman study stable antiretroviral therapy ( ART ) regimen randomize receive 1000 3000 IU vitamin D daily . The subject follow closely one year monitor compliance change bone health immune function .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>HIV+ African American Latina postmenopausal woman , aged 4070 , meet standard definition menopause : If 50 year old old amenorrhea &gt; 1year . If age 40 49 amenorrhea year FollicleStimulating Hormone ( FSH ) level equal great 20 mIU/ml ; amenorrheic chronically ill woman may hypothalamic dysfunction low FSH value , FSH 10 19 , serum estradiol level consistent menopause less equal 30pg/ml , determine postmenopausal . On stable antiretroviral therapy ( ART ) &gt; 2 year Undetectable HIV RNA ( viral load ) least 2 time past year ( RNA &lt; 400 ) Metabolic bone disease ( Paget 's disease , clinical osteomalacia , primary hyperparathyroidism , hypercalcemia ) Multiple myeloma , solid tumor metastasis ; Endocrinopathy ( hyperthyroidism , untreated hypothyroidism , Cushing 's syndrome , prolactinsecreting pituitary adenoma ) Renal insufficiency ( serum creatinine 1.5 mg/dl ) Liver disease ( AST , ALT , bilirubin , total alkaline phosphatase activity &gt; twice upper normal limit ) ; Intestinal disorder ( celiac disease , pancreatic insufficiency , Crohn 's disease , ulcerative colitis ) Current use glucocorticoid , anticonvulsant , anticoagulant , diuretic , methotrexate ; Current past use drug therapy osteoporosis ( raloxifene , bisphosphonates , calcitonin , PTH ) . Women estrogen exclude . Past estrogen use permit discontinue &gt; 1 year enrollment . If history low trauma fracture , T score &lt; 3 prevalent vertebral fracture Instant Vertebral Assessmentâ„¢ ( IVA ) , subject refer osteoporosis treatment appropriate . Severe vitamin D deficiency ( 25OHD level &lt; 10 ng/ml ) normal baseline serum vitamin D ( 25OHD &gt; 32 ng/ml ) . Subjects severe vitamin D deficiency may refer substudy , inclusion/exclusion criterion meet . Hypercalcemia history calciumcontaining kidney stone Known allergy/sensitivity hypersensitivity component study drug formulation Current imprisonment voluntary incarceration medical facility psychiatric illness Any condition , opinion site investigator , would compromise subject 's ability participate study</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Postmenopausal woman</keyword>
	<keyword>Vitamin D</keyword>
</DOC>